# Polaryx activates first site for Phase 2 trial of rare disease drug **Categories:** Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & development, Therapeutic Areas Polaryx Therapeutics has activated the first clinical trial site for its Phase 2 SOTERIA study, evaluating PLX-200 in four rare paediatric lysosomal storage disorders. Boys Town National Research Hospital in Nebraska will lead the initial patient screening, bringing the company closer to first dosing in a trial investigating CLN2 and CLN3 Batten disease, Krabbe disease and Sandhoff disease. The multicentre study will assess the safety, tolerability, pharmacokinetics and clinical activity of orally administered PLX-200 in children with the four conditions. #### Basket trial targets four rare neurological disorders SOTERIA is an open-label, single-arm Phase 2 trial designed to investigate whether PLX-200 could provide a treatment approach across several lysosomal storage disorders (LSDs). These inherited conditions result from defects affecting the breakdown or recycling of substances within cells, leading to the accumulation of storage materials and, in some cases, progressive neurological damage. The four conditions included in the study are associated with severe disease progression and substantial unmet treatment needs. The trial incorporates an initial six-patient sentinel group to assess early safety and tolerability before broader enrolment. The planned study population is 24 participants across the four disease cohorts. For the CLN2 and CLN3 cohorts, researchers will compare clinical outcomes with established natural history data to help assess potential treatment effects. Natural history studies track disease progression in patients who are not receiving the investigational treatment. The study is designed to provide proof-of-concept data to inform further development of PLX-200 and potential future registrational trials. #### First US site begins patient screening Boys Town National Research Hospital is the first of six planned US clinical trial sites to be activated. Polaryx expects the remaining five sites to be operational by the end of the first quarter of 2027. The company also submitted clinical trial applications to the European Medicines Agency (EMA) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in October 2026, seeking to extend the study into Europe and the UK. PLX-200 has received US Food and Drug Administration (FDA) Fast Track Designation for all four indications being investigated. The FDA previously authorised the company to proceed with SOTERIA in October 2025. Fast Track Designation is intended to facilitate the development and regulatory review of treatments addressing serious conditions with unmet medical needs. It does not constitute marketing approval. Alex Yang, chair and CEO of Polaryx Therapeutics, said: “The activation of our first SOTERIA site represents an important step in translating the groundwork we have completed into clinical execution.” He added that the company was pleased to begin the next phase with the Boys Town team as it works towards first patient dosing. #### PLX-200 development programme PLX-200 is an oral small molecule drug candidate being developed to address lysosomal dysfunction and associated neuroinflammation. The company’s preclinical research has investigated its potential to activate PPARα, a receptor involved in regulating cellular processes, including the expression of transcription factor EB (TFEB), which plays a role in lysosomal biogenesis and cellular waste clearance. Polaryx is investigating whether these effects could help reduce the accumulation of disease-associated storage materials and limit neuronal damage across different LSDs. The company has also received regulatory authorisation for separate clinical development programmes targeting CLN2 and CLN3 disease. SOTERIA is intended to generate further clinical evidence across all four indications and help determine the next steps for PLX-200’s development. The trial is registered on ClinicalTrials.gov under identifier NCT07740512.

Polaryx Therapeutics has activated the first clinical trial site for its Phase 2 SOTERIA study, evaluating PLX-200 in four rare paediatric lysosomal storage disorders.

Boys Town National Research Hospital in Nebraska will lead the initial patient screening, bringing the company closer to first dosing in a trial investigating CLN2 and CLN3 Batten disease, Krabbe disease and Sandhoff disease.

The multicentre study will assess the safety, tolerability, pharmacokinetics and clinical activity of orally administered PLX-200 in children with the four conditions.

Basket trial targets four rare neurological disorders

SOTERIA is an open-label, single-arm Phase 2 trial designed to investigate whether PLX-200 could provide a treatment approach across several lysosomal storage disorders (LSDs).

These inherited conditions result from defects affecting the breakdown or recycling of substances within cells, leading to the accumulation of storage materials and, in some cases, progressive neurological damage.

The four conditions included in the study are associated with severe disease progression and substantial unmet treatment needs.

The trial incorporates an initial six-patient sentinel group to assess early safety and tolerability before broader enrolment. The planned study population is 24 participants across the four disease cohorts.

For the CLN2 and CLN3 cohorts, researchers will compare clinical outcomes with established natural history data to help assess potential treatment effects. Natural history studies track disease progression in patients who are not receiving the investigational treatment.

The study is designed to provide proof-of-concept data to inform further development of PLX-200 and potential future registrational trials.

First US site begins patient screening

Boys Town National Research Hospital is the first of six planned US clinical trial sites to be activated. Polaryx expects the remaining five sites to be operational by the end of the first quarter of 2027.

The company also submitted clinical trial applications to the European Medicines Agency (EMA) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in October 2026, seeking to extend the study into Europe and the UK.

PLX-200 has received US Food and Drug Administration (FDA) Fast Track Designation for all four indications being investigated. The FDA previously authorised the company to proceed with SOTERIA in October 2025.

Fast Track Designation is intended to facilitate the development and regulatory review of treatments addressing serious conditions with unmet medical needs. It does not constitute marketing approval.

Alex Yang, chair and CEO of Polaryx Therapeutics, said: “The activation of our first SOTERIA site represents an important step in translating the groundwork we have completed into clinical execution.”

He added that the company was pleased to begin the next phase with the Boys Town team as it works towards first patient dosing.

PLX-200 development programme

PLX-200 is an oral small molecule drug candidate being developed to address lysosomal dysfunction and associated neuroinflammation.

The company’s preclinical research has investigated its potential to activate PPARα, a receptor involved in regulating cellular processes, including the expression of transcription factor EB (TFEB), which plays a role in lysosomal biogenesis and cellular waste clearance.

Polaryx is investigating whether these effects could help reduce the accumulation of disease-associated storage materials and limit neuronal damage across different LSDs.

The company has also received regulatory authorisation for separate clinical development programmes targeting CLN2 and CLN3 disease.

SOTERIA is intended to generate further clinical evidence across all four indications and help determine the next steps for PLX-200’s development.

The trial is registered on ClinicalTrials.gov under identifier NCT07740512.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox